Citovirax

Citovirax is an injectable solution that contains the antiviral agent ganciclovir. Marketed in the European Union as a prescription‑only medication, this formulation delivers ganciclovir intravenously for systemic treatment. Ganciclovir belongs to the antiviral drug class and works by inhibiting viral DNA polymerase after intracellular phosphorylation, thereby preventing replication of cytomegalovirus. Citovirax is used under medical supervision for approved CMV‑related indications in clinical practice and patient care.

Citovirax is indicated for the treatment and prevention of cytomegalovirus (CMV) infections in specific patient populations.

- Treatment of systemic CMV disease such as CMV pneumonia, colitis, or hepatitis. - Management of CMV retinitis in immunocompromised individuals, particularly those with AIDS or organ transplants. - Prophylactic therapy to prevent CMV infection in solid‑organ or hematopoietic stem‑cell transplant recipients. - Treatment of CMV infection in patients with weakened immune systems due to chemotherapy or other immunosuppressive conditions. - Use as part of combination therapy when monotherapy is insufficient for severe CMV disease.

Adverse reactions to Citovirax may vary in frequency and severity; they are typically reported during or after intravenous administration.

Common: - Injection‑site pain, erythema, or phlebitis. - Mild fever, chills, or headache. - Transient elevations in liver enzymes (ALT, AST). - Nausea or vomiting. - Diarrhea.

Serious: - Neutropenia or other significant bone‑marrow suppression. - Acute kidney injury or worsening renal function. - Severe hypersensitivity reactions, including rash, angioedema, or anaphylaxis. - Seizures or neurotoxicity. - Thrombocytopenia. - Significant drug‑resistant CMV infection.

Before initiating Citovirax therapy, clinicians should evaluate patient-specific factors and monitor for potential complications associated with antiviral treatment.

- Assess renal function; dose adjustment may be required in patients with impaired clearance. - Perform baseline complete blood count (CBC) and monitor for neutropenia or thrombocytopenia during therapy. - Monitor liver function tests regularly, especially in patients with pre‑existing hepatic disease. - Use caution in pregnant or breastfeeding women, as safety data are limited. - Avoid concurrent use with other nephrotoxic or myelosuppressive agents when possible. - Evaluate for potential drug‑resistant CMV strains in patients with prior antiviral exposure.

Citovirax can interact with other medicines, influencing its efficacy or increasing toxicity; awareness of these interactions supports safe use.

Avoid: - Concomitant use with other strong nephrotoxic agents (e.g., aminoglycosides, amphotericin B) should be avoided due to additive renal toxicity. - Co‑administration with myelosuppressive chemotherapy agents should be avoided because of heightened risk of bone‑marrow suppression.

Use with caution: - Use with caution when combined with other antiviral agents such as foscarnet, as additive hematologic toxicity may occur. - Caution is advised when prescribing with drugs that are highly protein‑bound, which may alter ganciclovir plasma levels. - Adjust dosage when used with medications that affect renal tubular secretion (e.g., probenecid).